Led, isn't it up to the patent office to determine if a new patent infringes on another's patent?

And do we know if Pfizer's European patent application was approved? 

And as it seems Pfizer's application applies to the one indication that being Friedreich's Ataxia and nothing else. Seeing that Resverlogix is not making the same claim with RVX-208 as Pfizer re the Friedreich's Ataxia indication does it really matter. In their patent they list a number of compounds RVX-208 being one of them. 

The article you stated says..... "It noted in its patent application that Resverlogix has already developed a therapy called apabetalone (RVX-208) that is based on the compounds.".... Seemingly, Pfizer already admitted that Resverlogix developed the compound that would benefit Pfizer should they be successful with their application. I don't see any rivalry between Resverlogix and Pfizer. The collaboration between Zenith and Pfizer as of late certainly helps to smooth things over between them. 
 

IMO, Koo